Sanofi Genzyme (Korea), a division of Sanofi Genzyme (Korea), announced on November 3 and 4 that it will share information on various heart diseases and discuss the latest trends in treatment and research. The Sanofi Cardiology Symposium was successfully completed.
At the Sanofi Symposium, Fabry disease, a rare hereditary disease characterized by cardiac ischemia and cardiac hypertrophy, is one of the major diseases. In addition, the Sanofi Group, including Plavix, Roberitto and Afrobel, tried to integrate the heart disease-related brand with an integrated approach to heart disease, including myocardial infarction, heart failure and hypertension. About 80 cardiologists participated in the two-day event, and active discussions on the treatment and research of heart disease were conducted.
At the first symposium held on November 3, Prof. Kim Woo-sik (Kyunghee University Hospital, Kyunghee University Hospital, Kyunghee University Hospital) was the chairman of Kyung Hee University Medical Center and the latest knowledge on diagnosis and treatment of rare inherited Fabry disease and antiplatelet therapy in chronic heart disease.
The first lecture of the symposium focused on the possibility of potential patients based on genealogical analysis, taking into account the hereditary nature of Fabry disease ▲ Professor Jung Wook Jin of Gakcheon University (Gil Hospital) In addition, a lecture on " Fabry disease and timely treatment "by Professor Hong Gru of Yonsei University (Severance Hospital), followed by a lecture by Professor Chang Woo-jin of Sungkyunkwan University School of Medicine (Circulatory Organ of Samsung Changwon Hospital) The ideal management strategy for antiplatelet agents was presented.
On the 4th day of the event, Professor Park Chang-gyu of Koryo Medical Center (Department of Cardiology of Guro Hospital) will be the chairman and Professor Kim Hyun-soo of Koshin Medical University will discuss the management of hypertension with specific diseases such as kidney failure, diabetes and heart failure. I did my first lecture. (ACS) of the Department of Cardiology, Dong-San Hospital of Keimyung Medical University, and the & quot; Low Density Lipoprotein Cholesterol Management (LDL-C) & # 39; of Professor Hong Soon- Management of antiplatelet drugs in the management of phagocytosis.
"Sanofi is striving to improve patient care and social awareness of diseases based on a portfolio of diverse heart conditions ranging from hypertension to rare diseases such as Fabry disease," said Park Hee-kyung, I will always do my best to provide innovation in treatment and provide the best treatment environment for healthcare professionals. "
Sanofi is an antiplatelet agent used in the prevention of cardiovascular diseases such as myocardial infarction, stroke and peripheral arterial disease, including Fabrice, an alternative to Fabry disease, which is approved by the US Food and Drug Administration (EMA) Rabelito 4, the first compound in Korea combined with Irbesartan, a therapeutic agent for ARB hypertension, and Atorvastatin, a statin-based treatment for hyperlipidaemia, and Afro Bell, an antihypertensive drug.
<© 2018 메디파나뉴스, 무단 전재 및 배포금지>The Korean Medicinal News Center & # 39; MEDIPANA NEWS